Where you can find opportunities in this market.
Our new report will show you how the market for antithrombotic and anticoagulant drugs will develop. You can indentify where the greatest opportunities will lie. There will be trends to watch from 2010 onwards, especially product launches and areas of revenue growth. You can have our report today, staying ahead.
We show how you can benefit from the sector’s developments and potential. There remain unmet therapeutic needs. New drugs with improved safety and efficacy can gain significant market shares from 2010 onwards. Novel and generic drug producers can benefit from this sector from 2010 to 2025, as our new report shows and explains.
Antithrombotic/Anticoagulant Drugs: World Market Prospects 2010-2025 covers the following therapeutic categories:
• Platelet aggregation inhibitors
• Heparins
• Fibrinolytics
• Vitamin K antagonists
• Direct thrombin inhibitors
• Other agents.
What therapeutic agents are likely to enter the market from 2010 onwards, and can they dominate? Where will the best commercial opportunities lie? How will industry/market drivers and restraints affect the sector? We show you commercial opportunities and challenges for the sector, especially revenue trends for 2010 to 2025.
You will discover commercial prospects at global, national, sub-market and product levels. You can assess the sector’s potential today. We aim to save you time and benefit your work.
Industry and market analysis to save you time and aid your decisions
Our new report examines the antithrombotic and anticoagulant sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data. You can discover strengths, weaknesses, opportunities and threats in the sector. We include many tables and figures and an expert interview - shown in the contents lists with this message.
Why you need Antithrombotic/Anticoagulant Drugs: World Market Prospects 2010-2025
This report gives you the following benefits in particular:
• You will review the current market for antithrombotic/anticoagulant drugs
• You will analyse the overall antithrombotic/anticoagulant drugs market, receiving a global sales forecast for 2010 to 2025
• You will receive sales forecasts for submarkets from 2010 to 2025, with discussions
• You will receive sales forecasts for leading products from 2010 to 2025, with discussions of market potential and competition
• You will receive sales forecasts for leading national markets from 2010 to 2025 (US, Japan, France, Germany, UK, Spain, Italy, China and India)
• You will analyse the drivers, restraints, competition and opportunities influencing the antithrombotic/anticoagulant drug sector
• You will assess the R&D pipeline, seeing important developments
• You will discover expert views from our survey.
Our study gives you answers and trends - we aim to save you time and aid your decisions.
You can have this report today
Our new report can benefit everybody interested in the antithrombotic and anticoagulant drug industry and market. We forecast commercial potential, discovering trends. Do you want to harness those opportunities? You can stay ahead by ordering our report now. Please let us know how we can help.
1. Executive Summary
1.1 Antithrombotic/Anticoagulant Drug Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to Blood Clotting and Related Disorders
2.1 The Functions of Blood
2.2 Haemostasis, Coagulation and Thrombosis
2.3 Types of Thrombosis
2.3.1 Venous Thrombosis
2.3.1.1 Deep Vein Thrombosis
2.3.1.2 Portal Vein Thrombosis
2.3.2 Arterial Thrombosis
2.4 Stroke
2.5 Myocardial Infarction
2.6 Acute Coronary Syndrome
2.7 Risk Factors
3. Antithrombotic/Anticoagulant Treatments
3.1 Platelet Aggregation Inhibitors
3.1.1 Glycoprotein Inhibitors
3.1.2 COX Inhibitors and Aspirin
3.1.3 Thienopyridines
3.2 Heparins
3.3 Fibrinolytics
3.3.1 Streptokinase and Urokinase
3.3.2 Tissue Plasminogen Activators
3.3.3 Other Thrombolytic Agents
3.4 Vitamin K Antagonists
3.5 Direct Thrombin Inhibitors
4. The Antithrombotic/Anticoagulant Drug Market, 2010-2025
4.1 The Antithrombotic/Anticoagulant Drug Market in 2009
4.2 Antithrombotic/Anticoagulant Drug Market Forecast, 2010-2025
4.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
4.3.1 The Leading Therapeutic Classes in 2009
4.3.2 Leading Therapeutic Class Forecasts, 2010-2025
4.4 Platelet Aggregation Inhibitors
4.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2009
4.4.2 The Future of Platelet Aggregation Inhibitors, 2010-2025
4.5 Heparins
4.5.1 The Heparins Market in 2009
4.5.2 Heparin Market Forecast, 2010-2025
4.6 Fibrinolytics
4.6.1 The Fibrinolytics Market in 2009
4.6.2 Fibrinolytics Market Forecast, 2010-2025
4.7 Vitamin K Antagonists
4.7.1 The Vitamin K Antagonists Market in 2009
4.7.2 Vitamin K Antagonists Market Forecast, 2010-2025
4.8 Direct Thrombin Inhibitors
4.8.1 The Direct Thrombin Inhibitors Market in 2009
4.8.2 Direct Thrombin Inhibitors Forecast, 2010-2025
4.9 Chapter Summary - The Anticoagulant/Antithrombotic Drug Market
5. The Leading Antithrombotic/Anticoagulant Drugs, 2010-2025
5.1 The 10 Leading Drugs Accounted for over 70% of the Global Antithrombotic/ Anticoagulant Market in 2009
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant in 2009
5.2.2 Plavix Sales Forecast, 2010-2025
5.2.3 Generic Competition for Plavix
5.2.4 Branded Competition: Marketed and in the Pipeline
5.3 Lovenox - Commercial Prospects
5.3.1 Lovenox Sales, 2009
5.3.2 Lovenox Sales Forecast, 2010-2025
5.3.3 Competition for Lovenox
5.4 Pletaal - Commercial Prospects
5.4.1 Pletaal Sales, 2009
5.4.2 Pletaal Sales Forecast, 2010-2025
5.5 Asasantin - Commercial Prospects
5.5.1 Asasantin Sales, 2009
5.5.2 Asasantin Sales Forecast, 2010-2025
5.6 Fragmin - Commercial Prospects
5.6.1 Fragmin Sales, 2009
5.6.2 Fragmin Sales Forecast, 2010-2025
5.6.3 Fragmin’s Life Cycle Management and Competition
5.7 Opalmon - Commercial Prospects
5.7.1 Opalmon Sales, 2009
5.7.2 Opalmon Sales Forecast, 2010-2025
5.8 Aspirin Cardio - Commercial Prospects
5.8.1 Aspirin Cardio Sales, 2009
5.8.2 Aspirin Cardio Sales, 2010-2025
5.8.3 OTC Treatments for the Prevention of Cardiovascular Disease?
5.9 Angiomax - Commercial Prospects
5.9.1 Angiomax - The Leading Direct Thrombin Inhibitor in 2009
5.9.2 Angiomax Sales Forecast, 2010-2025
5.10 Arixtra - Commercial Prospects
5.10.1 Arixtra Sales, 2009
5.10.2 Arixtra Sales Forecast, 2010-2025
5.11 Activase - Commercial Prospects
5.11.1 Activase Sales, 2009
5.11.2 Activase Sales Forecast, 2010-2025
5.12 Chapter Summary - The Top 10 Anticoagulant/Antithrombotic Products, 2010-2025
6. Issues Affecting the Antithrombotic/Anticoagulant Drug Market
6.1 Principal Market Drivers
6.1.1 Increasing Prevalence of Disease Drives the Market
6.1.2 Risk Factors: Management Rather than Cure
6.1.3 Opportunities for Continuing Growth
6.1.4 Advances in Technology are Likely to Bring Benefits to the Market
6.2 Market Restraints
6.2.1 The Threat of Generic Products
6.2.2 Downward Cost Pressures
6.2.3 A Buyer’s Market?
7. The Antithrombotic/Anticoagulant Drug Pipeline
7.1 Late-Stage R&D Pipeline for Platelet Aggregation Inhibitors, 2010
7.1.1 AstraZeneca’s Brilinta
7.1.2 Servier’s Terutroban
7.1.3 Novartis’ Elinogrel
7.2 Late-Stage Pipeline for Heparins, 2010
7.2.1 Sanofi-Aventis’ Octaparine
7.3 Late-Stage Pipeline for Fibrinolytics, 2010
7.3.1 Lundbeck’s Desmoteplase
7.4 Late-Stage Pipeline for Vitamin K inhibitors, 2010
7.4.1 ARYx’ Tecarfarin
7.5 Late-Stage Pipeline for Direct Thrombin Inhibitors, 2010
7.5.1 Merck’s Vorapaxar
7.6 Other Pipeline Antithrombotic/Anticoagulant Drugs, 2010
7.6.1 Vernalis’ V10153
7.6.2 AstraZeneca’s AZD 6428
7.7 R&D Pipeline Analysis - Concluding Thoughts
8. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2010-2025
8.1 Leading National Markets in 2009
8.2 Leading National Markets: Sales Forecasts, 2010-2025
8.3 The US Antithrombotic/Anticoagulant Drug Market, 2010-2025
8.4 Japanese Antithrombotic/Anticoagulant Drug Market, 2010-2025
8.5 Leading Antithrombotic/Anticoagulant Drug Markets in Europe, 2010-2025
8.6 Antithrombotic/Anticoagulant Drug Market in China, 2010-2025
8.7 Antithrombotic/Anticoagulant Drug Market in India, 2010-2025
9. Expert Opinion
9.1 Interview with Professor Stan Heptinstall
9.1.1 Key Areas of Research
9.1.2 Limitations of Current Drugs
9.1.3 Unmet Needs
10. Conclusions
10.1 The World Antithrombotic/Anticoagulant Drug Market in 2009
10.2 Future of the Antithrombotic/Anticoagulant Drug Market
10.2.1 Challenges and Opportunities
10.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes
10.4 Leading Products in the Antithrombotic/Anticoagulant Drug Market
10.5 Geographical Breakdown of the Market
List of Tables
Table 4.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016
Table 4.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2025
Table 4.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2009
Table 4.4 Leading Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016
Table 4.5 Leading Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2025
Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2009
Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2016
Table 5.3 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2017-2025
Table 5.4 Plavix Sales Forecast ($m), 2010-2016
Table 5.5 Plavix Sales Forecast ($m), 2017-2025
Table 5.6 Lovenox Sales Forecast ($m), 2010-2016
Table 5.7 Lovenox Sales Forecast ($m), 2017-2025
Table 5.8 Pletaal Sales Forecast ($m), 2010-2016
Table 5.9 Pletaal Sales Forecast ($m), 2017-2025
Table 5.10 Asasantin Sales Forecast ($m), 2010-2016
Table 5.11 Asasantin Sales Forecast ($m), 2017-2025
Table 5.12 Fragmin Sales Forecast ($m), 2010-2016
Table 5.13 Fragmin Sales Forecast ($m), 2017-2025
Table 5.14 Opalmon Sales Forecast ($m), 2010-2016
Table 5.15 Opalmon Sales Forecast ($m), 2017-2025
Table 5.16 Aspirin Cardio Sales Forecast ($m), 2010-2016
Table 5.17 Aspirin Cardio Sales Forecast ($m), 2017-2025
Table 5.18 Angiomax Sales Forecast ($m), 2010-2016
Table 5.19 Angiomax Sales Forecast ($m), 2017-2025
Table 5.20 Arixtra Sales Forecast ($m), 2010-2016
Table 5.21 Arixtra Sales Forecast ($m), 2017-2025
Table 5.22 Activase Sales Forecast ($m), 2010-2016
Table 5.23 Activase Sales Forecast ($m), 2017-2025
Table 6.1 SWOT Analysis: Anticoagulant/Antithrombotic Drug Market, 2010
Table 7.1 Late-Stage Platelet Aggregation Inhibitors R&D Pipeline, 2010
Table 7.2 Late-Stage Heparin Drugs R&D Pipeline, 2010
Table 7.3 Late-Stage Fibrinolytics R&D Pipeline, 2010
Table 7.4 Late-Stage Direct Thrombin Inhibitors R&D Pipeline, 2010
Table 7.5 R&D Pipeline for Other Antithrombotic/Anticoagulant Drugs, 2010
Table 8.1 Leading National Markets for Antithrombotic/Anticoagulant Drugs ($bn), 2009
Table 8.2 Leading National Markets for Antithrombotic/Anticoagulant Drugs: Forecasts ($bn), 2010-2016
Table 8.3 Leading National Markets for Antithrombotic/Anticoagulant Drugs: Forecasts ($bn), 2017-2025
Table 8.4 Leading National Markets: Market Shares (%), 2009, 2015, 2020 & 2025
Table 10.1 Antithrombotic/Anticoagulant Drug Market ($bn), 2009, 2015, 2020 & 2025
List of Figures
Figure 4.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2025
Figure 4.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2009
Figure 4.3 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2025
Figure 4.4 Heparins: Market Forecast ($bn), 2010-2025
Figure 4.5 Fibrinolytics: Market Forecast ($bn), 2010-2025
Figure 4.6 Vitamin K Antagonists: Market Forecast ($bn), 2010-2025
Figure 4.7 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2025
Figure 4.8 Leading Antithrombotic/Anticoagulant Therapeutic Classes ($bn), 2009, 2015 & 2025
Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Market Shares (%), 2009
Figure 5.2 Plavix Sales Forecast ($m), 2010-2025
Figure 5.3 Lovenox Sales Forecast ($m), 2010-2025
Figure 5.4 Pletaal Sales Forecast ($m), 2010-2025
Figure 5.5 Asasantin Sales Forecast ($m), 2010-2025
Figure 5.6 Fragmin Sales Forecast ($m), 2010-2025
Figure 5.7 Opalmon Sales Forecast ($m), 2010-2025
Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2025
Figure 5.9 Angiomax Sales Forecast ($m), 2010-2025
Figure 5.10 Arixtra Sales Forecast ($m), 2010-2025
Figure 5.11 Activase Sales Forecast ($m), 2010-2025
Figure 8.1 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2009
Figure 8.2 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2015
Figure 8.3 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2020
Figure 8.4 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2025
Figure 8.5 The US Antithrombotic/Anticoagulant Drug Market ($bn), 2010-2025
Figure 8.6 The Japanese Antithrombotic/Anticoagulant Drug Market ($bn), 2010-2025
Figure 8.7 Leading Antithrombotic/Anticoagulant Drug Markets in Europe ($bn), 2010-2025
Figure 8.8 The Antithrombotic/Anticoagulant Drug Market in China & India ($bn), 2010-2025
Figure 10.1 The Antithrombotic/Anticoagulant Market: Sales ($bn), 2010-2025
Figure 10.2 Leading Therapeutic Classes: Sales ($bn), 2010-2025
Figure 10.3 Leading Products: Sales ($m), 2009, 2015 & 2025
Figure 10.4 Leading National Markets: Sales ($bn), 2009, 2015 & 2025
Acino Pharma
Amphastar Pharmaceuticals
Apotex
ARCA Discovery
Archemix
Arena Pharmaceuticals
ARYx Therapeutics
AstraZeneca
Barr Pharmaceuticals (now a part of Teva)
Bayer HealthCare
Bayer Schering Pharma
Berlex Pharmaceuticals
Bharat Pharma
BioInvent
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Cardiome Pharma
Daiichi Sankyo
Dainippon Sumitomo Pharma
deCODE genetics
Eisai Pharmaceuticals
Eli Lilly and Company
Endotis Pharma
European Medicines Agency (EMA/EMEA)
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline (GSK)
Hexal
Indigo Pharmaceuticals
Japanese Society for Spine Surgery and Related Research
Johnson & Johnson
Kyowa Hakko
Ligand Pharmaceuticals
Lundbeck
Merck & Co.
Mitsubishi Kasei
Momenta Pharmaceuticals
Myriad Genetics
New England Journal of Medicine
Nissan Chemical
Novartis
Ono Pharmaceutical Co.
Organon (now part of Merck & Co.)
Otsuka Pharmaceuticals
PAION
ParinGenix
Pfizer
Pharmacia (acquired by Pfizer in 2002)
Portola Pharmaceuticals
POZEN
Ranbaxy (now part of Daiichi Sankyo)
ratiopharm
Roche
ROVI Pharmaceuticals
Sanofi-Aventis
Servier Laboratories
Taisho Pharmaceutical Co.
Talecris Biotherapeutics
Teva Pharmaceutical Industries
The Aptamer Therapeutics Company
The Medicines Company
The US Federal Trade Commission
ThromboGenics
Trigen Pharma
University of Nottingham, UK
Vernalis Pharmaceuticals
Watson Pharmaceuticals
Other selected research from the 'Drugs' category:
Liver Cancer Drug Pipeline Update 2012
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021
Other selected research from the 'Cardiovascular' category:
Cardiac Rhythm Management Devices World Markets
Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021